drugset / Trial / NCT02625090
An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
NaSingle-groupOpen-labelTreatment
Summary
The purpose of study EP0073 is to assess the long-term safety, tolerability, and efficacy during 5 years of treatment with the drug UCB0942 in patients with highly drug-resistant focal epilepsy. Also, the effects of UCB0942 on the patient's quality of life will be explored.
Timeline
- Start
- 2015-12-03
- Primary completion
- 2020-11-24
- Completion
- 2020-11-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Padsevonil | Small molecule | 100 mg | Oral |
| Subject | Padsevonil | Small molecule | 200 mg | Oral |
| Subject | Padsevonil | Small molecule | 400 mg | Oral |
| Subject | Padsevonil | Small molecule | 600 mg | Oral |
| Subject | Padsevonil | Small molecule | 800 mg | Oral |